USANA Health Sciences (USNA) Tops Q4 EPS by 44c, Offers Guidance

USANA Health Sciences (NYSE: USNA) reported Q4 EPS of $1.87, $0.44 better than the analyst estimate of $1.43. Revenue for the quarter came in at $310.5 million versus the consensus estimate of $291.54 million.

GUIDANCE:

USANA Health Sciences sees FY2021 EPS of $6.00-$6.45, versus the consensus of $5.77. USANA Health Sciences sees FY2021 revenue of $1.21-1.27 billion, versus the consensus of $1.19 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth